72 Use of Palivizumab in Canada; Data from the CARESS registry 2005–2017

ABSTRACT: Abstract

Background

The Canadian Registry of Palivizumab (CARESS) tracks palivizumab utilization and hospitalizations for respiratory illness (RI) and respiratory syncytial virus (RSVH) in high-risk infants, whatever the indication. The decision to administer palivizumab is taken by individual clinicians at the participating centers.

Objectives

To provide insight into the current management (utilization, adherence) with palivizumab of children at high risk of RSV infection in the tertiary care centers and community settings through the development of a Canadian Registry Database. A registry may give some indication of safety and effectiveness of an intervention in real life situations in many, uncommon medical conditions.

Design/Methods

A prospective, observation

SUBMITTER: Mitchell I 

PROVIDER: S-EPMC6543371 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature